# Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia

> **NCT02544789** · PHASE2 · COMPLETED · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 44 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Clofarabine

## Key facts

- **NCT ID:** NCT02544789
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-11
- **Final completion:** 2012-05
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2015-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02544789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02544789, "Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02544789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*